Dr. Eric Masson is Vice President, Early Clinical Development at Arvinas. Dr. Masson has over 24 years of experience in the biotechnology industry and joins Arvinas after serving as Vice President, Clinical Pharmacology and Pharmacometrics at Biogen where he was responsible for those disciplines spanning from Investigational New Drug (IND) through Phase IV. Prior to Biogen, Dr. Masson’s held leadership roles of increasing responsibility at AstraZeneca, Bristol-Myers Squibb, Novartis and Anapharm, Inc. Dr. Masson also served as a faculty member at the Université Laval in Quebec, Canada. Over his career, he played a key role in successful filings and approvals of the following medicines: Ipilimumab (Yervoy®), Nivolumab (Opdivo®), Osimertinib (Tagrisso®), Acalabrutinib (Calquence®), Diroximel Fumarate (Vumerity®), and Aducanumab (Aduhelm®).
Dr. Masson received his B.Pharm from Université Laval, his PharmD from the State University of New York at Buffalo and completed his postdoctoral fellowship in clinical pharmacology at St. Jude’s Children’s Research Hospital.